Sartorius AG

Last updated
Sartorius AG
Company type Aktiengesellschaft
ISIN
Industry Pharmaceutical and Laboratory Equipment
Founded1870;154 years ago (1870)
Göttingen, Germany
FounderFlorenz Sartorius
Headquarters Göttingen, Germany
Area served
Worldwide
Key people
  • Joachim Kreuzburg (CEO & Executive Board Chair)
  • René Fáber (Executive Board Member)
  • Alexandra Gatzemeyer (Executive Board Member)
  • Florian Funck (CFO)
RevenueDecrease2.svg €3.4 billion (2023) [1]
Number of employees
14,614 (end 2023) [1]
Website sartorius.com

Sartorius AG is an international pharmaceutical and laboratory equipment supplier, covering the segments of Bioprocess Solutions and Lab Products & Services. In September 2021, Sartorius has been admitted to the DAX, Germany's largest (Blue chip) stock market index. [2] As a leading partner to the biopharmaceutical research and industry, Sartorius supports its customers in the development and production of biotech drugs and vaccines - from the initial idea in the laboratory to commercial production. Sartorius conducts its operating business in the two divisions Bioprocess Solutions and Lab Products&Services. The divisions bundle their respective businesses according to the same application areas and customer groups. The divisions share some of the infrastructure and central services. [3]

Contents

Universal theodolite made by Florenz Sartorius, c. 1910 Universal theodolite, made by F Sartorius, Gottingen, c. 1910, TM30123 - Tekniska museet - Stockholm, Sweden - DSC01516.jpg
Universal theodolite made by Florenz Sartorius, c. 1910

History

1969
Sartorius tested moon rock collected during the Apollo 11 mission. [4]


Recent history (since 2000)

2000
Sartorius took over B. Braun Biotech International (BBI) from B. Braun Melsungen AG. BBI, the world's leading manufacturer of fermenters (bioreactor) and cell culture systems at the time, was integrated into the Sartorius group as Sartorius Stedim Systems GmbH (formerly Sartorius BBI Systems GmbH ), a subsidiary of Sartorius Stedim Biotech GmbH. [5]

Sartorius AG acquired the remaining shares in Viva Science and is now the sole owner. [6]

2005
Sartorius acquires 100% of the shares of Omnimark Instrument Corporation, Arizona, United States (moisture analyzers). [7]

2007
Sartorius merged its biotechnology division with the French biotech company Stedim S.A. The resulting Sartorius Stedim Biotech (SSB) is the world's leading technology provider for the biopharmaceutical industry. The new company is listed on the Paris stock exchange. [8] [9]

Sartorius took over the Toha Plast GmbH , which now operates under the name Sartorius Stedim Plastics . [10]

2008
Through its subgroup, SSB Sartorius acquired the Swiss-based Wave Biotech AG, a leading provider of single-use bioreactors. [11]

2011
Sartorius acquired the liquid handling business of the Finnish laboratory specialists Biohit. Thus, the Group expands its product portfolio in the field of laboratory instruments. [3] [12]

2013
A new production building for the injection molding of plastic parts was opened in Göttingen. In the same year, the new Asia sales center of the Sartorius Group was inaugurated in Shanghai, from which all sales and marketing activities for China and for the entire Asia region are controlled. [13] [14]

2015

In 2015, Sartorius Acquired cell line and process development Cellca. [15] By 2017, the subsidiary Sartorius Stedim Cellca was in operation, operating out of a rented facility in Laupheim, but by 2019 a new facility is slated to be occupied in the Eselsberg district of Ulm. [16]

2016
The company acquired two North American flow cytometry companies, IntelliCyt ($90 million) [17] and ViroCyt ($16 million). [18]

In July, the company, through SSB, acquired kSep Systems, which specialized in preparative centrifugation for recombinant proteins, vaccines, and cell therapy products. [19]

In November, the SSB subdivision opened a new bioanalytical and biosafety testing facility in Boston. [20]

2017
The company acquired cell-based assay and instrumentation firm Essen BioScience, from private equity owner SFW Capital Partners, for $320 million. [21]

A co-development agreement between Sartorius' Cellca subsidiary and Synpromics began to test Synpromics' customized synthetic promoters on Cellca's CHO Expression Platform. [16]

Another co-development agreement was inked with Nova Biomedical to develop a system for large-scale testing of diverse cell culture conditions. [22]

2019
The company acquired the Israel cell culture media developer and manufacturer Biological Industries. [23]

2020
The company acquired selected assets of Danaher Corporation, including products for the research and development of cell therapies. [24]

2021
The company acquired the German cell culture media manufacturer Xell AG, [25] the German cell and gene therapy raw materials supplier CellGenix GmbH [26] and the German bioanalytic company ALS Automated Lab Solutions GmbH. [27]

Products & Services

Sartorius Stedim Biotech

Sartorius Stedim BioOutsource

BioOutsource is a subsidiary of Sartorius Stedim Biotech [34]

Sartorius Stedim Cellca

See also

Related Research Articles

Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California. It became an independent subsidiary of Roche in 2009. Genentech Research and Early Development operates as an independent center within Roche. Historically, the company is regarded as the world's first biotechnology company.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

Pharming, a portmanteau of farming and pharmaceutical, refers to the use of genetic engineering to insert genes that code for useful pharmaceuticals into host animals or plants that would otherwise not express those genes, thus creating a genetically modified organism (GMO). Pharming is also known as molecular farming, molecular pharming, or biopharming.

<span class="mw-page-title-main">Danaher Corporation</span> American conglomerate

Danaher Corporation is an American global conglomerate founded in 1984 by brothers Steven and Mitchell Rales. Headquartered in Washington, D.C., the company designs, manufactures, and markets medical, industrial, and commercial products and services. Danaher was among the first companies in North America to adopt Kaizen principles, a Japanese lean manufacturing philosophy of continuous improvement and efficiency. The company held $78.5 billion in assets as of 2024.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

This page provides an alphabetical list of articles and other pages about biotechnology.

Eppendorf, a company with its registered office in Germany, develops, produces and sells products and services for laboratories around the world.

<span class="mw-page-title-main">Photobioreactor</span> Bioreactor with a light source to grow photosynthetic microorganisms

A photobioreactor (PBR) refers to any cultivation system designed for growing photoautotrophic organisms using artificial light sources or solar light to facilitate photosynthesis. Photobioreactors are typically used to cultivate microalgae, cyanobacteria, and some mosses. Photobioreactors can be open systems, such as raceway ponds, which rely upon natural sources of light and carbon dioxide. Closed photobioreactors are flexible systems that can be controlled to the physiological requirements of the cultured organism, resulting in optimal growth rates and purity levels. Photobioreactors are typically used for the cultivation of bioactive compounds for biofuels, pharmaceuticals, and other industrial uses.

<span class="mw-page-title-main">Thermo Fisher Scientific</span> Provisioner of scientific consumables, equipment, and services

Thermo Fisher Scientific Inc. is an American life, science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation (2013), Alfa Aesar (2015), Affymetrix (2016), FEI Company (2016), BD Advanced Bioprocessing (2018), and PPD (2021).

<span class="mw-page-title-main">Genedata</span> Swiss bioinformatics company

Genedata is a bioinformatics company that develops enterprise software solutions to accelerate biopharmaceutical research and development. Founded in 1997 by Othmar Pfannes, Genedata has since grown to approximately 400 employees. Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo positioning the company in the heart of biopharma clusters around the globe.

MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

<span class="mw-page-title-main">Virus counter</span> Instrument for quantification of viruses

The virus counter is an instrument for rapid quantification of viruses in liquid samples. It is a specialized flow cytometer that uses high-sensitivity fluorescence detection to give a direct measurement of the concentration of virus particles in a fraction of the time required for traditional plaque assays.

A single-use bioreactor or disposable bioreactor is a bioreactor with a disposable bag instead of a culture vessel. Typically, this refers to a bioreactor in which the lining in contact with the cell culture will be plastic, and this lining is encased within a more permanent structure. Commercial single-use bioreactors have been available since the end of the 1990s and are now made by several well-known producers.

<span class="mw-page-title-main">Evotec</span> German biopharmaceutical company

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development.

<span class="mw-page-title-main">Galena Biopharma</span> American pharmaceutical company

Galena Biopharma, Inc. was a publicly traded pharmaceutical company based in San Ramon, California. The company was founded in Worcester, Massachusetts. In 2011, it moved to Oregon, and in 2015 moved to San Ramon, California. Mark Schwartz was the company's president and chief executive officer. As of December 29, 2017, the company was acquired by Sellas Life Sciences Group Ltd. through a reverse merger transaction. Galena Biopharma was renamed to Sellas Life Sciences Group, Inc..

<span class="mw-page-title-main">Sotio</span> Czech biotechnology company

SOTIO Biotech is a Czech biotechnology company focused on clinical-stage research and development of innovative medicines for cancer with operations in Europe, North America, and Asia. The company has clinical programs which include a superagonist of the immuno-oncology target IL-15, a new generation of potent and stable antibody-drug conjugates (ADCs), proprietary technology designed to improve on the efficacy of CAR T therapies and a platform to streamline and enhance personalized cell therapies.

<span class="mw-page-title-main">Uwe Marx</span> German physician and biotechnologist (born 1964)

Uwe Marx is a German physician and biotechnologist, and one of the world’s leading researchers in the fields of organ-on-a-chip technology and antibody production.

Ginkgo Bioworks is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

<span class="mw-page-title-main">WuXi Biologics</span> Chinese pharmaceutical company

WuXi Biologics is a global Contract Research Development and Manufacturing Organization (CRDMO) that provides open-access, integrated technology platforms for biologics drug development.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.

References

  1. 1 2 "Sartorius Group 2023 Annual Report". Sartorius Group. Retrieved 10 July 2024.
  2. ↑ "Jetzt auch im Dax: Sartorius und Symrise spielen in der ersten Liga". www.hna.de (in German). 2021-09-04. Retrieved 2023-12-23.
  3. 1 2 "Sartorius | Biopharma, Laboratory, Applied & Life Sciences". Sartorius. Retrieved 2022-09-16.
  4. ↑ "How Sartorius Technologies Support Research in Space". Sartorius. Retrieved 23 November 2024.
  5. ↑ "B. Braun Biotech International GmbH". Life-Sciences-Europe.com - The European Life Sciences Web Portal. Retrieved 2024-10-25.
  6. ↑ "Sartorius erhöht Beteiligung an der Vivascience". GSC Research (in German). Retrieved 2024-11-12.
  7. ↑ "Sartorius acquires Omnimark". Manufacturing Chemist. Retrieved 2024-11-12.
  8. ↑ "Sartorius weiht neues Werk in China ein". www.chemie.de (in German). Retrieved 2022-09-16.
  9. ↑ "Sartorius erweitert in Göttingen - faktor". 2015-09-24. Archived from the original on 2015-09-24. Retrieved 2022-09-16.
  10. ↑ "Sartorius acquires Toha Plast". outsourcing-pharma.com. Retrieved 2024-11-12.
  11. ↑ "Sartorius Stedim Biotech Acquires Wave Biotech". BioPharm International. Retrieved 2024-11-12.
  12. ↑ "Sartorius Concludes Agreement to Acquire the Liquid Handling Business of the Finnish Laboratory Supplier Biohit". Business Wire. Retrieved 2024-11-12.
  13. ↑ "Sartorius | Biopharma, Laboratory, Applied & Life Sciences". Sartorius. Retrieved 2022-08-20.
  14. ↑ "Sartorius: Neue Produktionshalle für die Kunststoffverarbeitung". KunststoffWeb (in German). Retrieved 2022-08-20.
  15. ↑ "Sartorius Acquires Cell Line and Process Developer Cellca". GEN News Highlights. Genetic Engineering & Biotechnology News. 2 July 2015. Retrieved 2 December 2017.
  16. 1 2 3 "Insights". Columns. Genetic Engineering & Biotechnology News. Vol. 37, no. 1. 1 January 2017. Bioprocessing: Synthetic Promoters Promise to Boost Mammalian Cell Platform’s Yields. Retrieved 2 December 2017.
  17. ↑ Cardillo, Joe (28 June 2016). "Fast-growing ABQ biotech startup acquired for $90 million in cash". Albuquerque Business First. Retrieved 1 December 2017.
  18. ↑ "Sartorius Acquires ViroCyt for $16M". Genetic Engineering & Biotechnology News. Retrieved 2024-11-12.
  19. ↑ DePalma, Angelo (15 January 2017). "Just Enough Downstream Innovation". Feature Articles. Genetic Engineering & Biotechnology News. Vol. 37, no. 2. A New Spin. Retrieved 2 December 2017.
  20. ↑ "Sartorius Sees Future in New Boston Lab". Columns. Genetic Engineering & Biotechnology News. Vol. 37, no. 1. 1 January 2017. Retrieved 2 December 2017.
  21. ↑ "Sartorius to Buy Essen for $320M to Acquire Live-Cell Imaging Platform". GEN News Highlights. Genetic Engineering & Biotechnology News. 3 March 2017. Retrieved 1 December 2017.
  22. ↑ "Sartorius, Nova to Combine Bioreactor and Cell Analyzer Platforms". GEN News Highlights. Genetic Engineering & Biotechnology News. 17 May 2017. Retrieved 2 December 2017.
  23. ↑ "$50m deal helps make Sartorius media player again - Bioprocess Insider". BioProcess International. 9 December 2019. Retrieved 7 January 2022.
  24. ↑ Macdonald, Gareth John (12 May 2020). "Sartorius' Acquisition of Danaher Techs Fits Demand for Process Intensification". GEN - Genetic Engineering and Biotechnology News. Retrieved 7 January 2022.
  25. ↑ "Sartorius buys Xell among 'lively' M&A environment - Bioprocess Insider". BioProcess International. 30 July 2021. Retrieved 7 January 2022.
  26. ↑ "Sartorius acquires majority stake in CellGenix". biopharma-reporter.com. Retrieved 7 January 2022.
  27. ↑ "Milbank Advises Sartorius on Acquisition of Majority Stake in ALS Automated Lab Solutions". Milbank LLP. Retrieved 7 January 2022.
  28. ↑ Thomas, Dave (1 October 2017). "Evaluation of an Automated Cryovial Dispensing System for Cell Banking". Tutorials. Genetic Engineering & Biotechnology News. Vol. 37, no. 17. Retrieved 2 December 2017.
  29. ↑ DePalma, Angelo (1 August 2017). "True to Scale: Benchtop Bioreactors". Feature Articles. Genetic Engineering & Biotechnology News. Vol. 37, no. 14. Sartorius Stedim Biotech’s 2nd-Generation STR Bioreactors. Retrieved 2 December 2017.
  30. ↑ Zijlstra, Gerben; Gupta, Priyanka (15 September 2017). "Supplement: Moving toward Continuous Bioprocessing". Feature Articles. Genetic Engineering & Biotechnology News. Vol. 37, no. 16. Retrieved 2 December 2017.
  31. ↑ DePalma, Angelo (1 May 2017). "Scaledown Keeps Processes on the Up and Up". Genetic Engineering & Biotechnology News. Vol. 37, no. 9. Platform Options. Retrieved 2 December 2017.
  32. ↑ DePalma, Angelo (1 June 2017). "Chromatography Makes Room for Biomolecular Diversity". Genetic Engineering & Biotechnology News. Vol. 37, no. 11. Heavier Load for Membranes. Retrieved 2 December 2017.
  33. ↑ Peuker, Thorsten (1 May 2017). "Supplement: Strategies to Overcome Modular Design Challenges". Featured Articles. Genetic Engineering & Biotechnology News. Vol. 37, no. 9. Retrieved 2 December 2017.
  34. 1 2 "Insights". Columns. Genetic Engineering & Biotechnology News. Vol. 37, no. 11. 1 June 2017. Bioprocessing: Sartorius Stedim Biotech Launches Chemistry Testing Services. Retrieved 2 December 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.